Knowledge Hub · Lu-177 n.c.a.
The starting material that decidesevery Lu-177 labelling yield.
Lu-177 is the workhorse therapeutic β⁻ emitter of contemporary theranostics — PSMA-617 for mCRPC, DOTATATE for NETs, FAPI for tumour-stroma protocols. What separates a good clinical batch from a marginal one is set upstream of the labelling kit: how much cold lutetium is in the matrix, how much Lu-177m metastable contamination tails into long-term organ dose, and how tightly the radionuclidic purity meets the pharmacopoeia. This page unpacks what "no-carrier-added" actually buys.
Why this matters
Six things n.c.a. Lu-177 delivers, explained simply
What "n.c.a." actually means
No cold lutetium competing for the labelling kit
Lu-177 can be produced two ways. Carrier-added production (direct neutron capture on Lu-176 targets) ships a matrix dominated by stable Lu-175/176. n.c.a. production routes the activity through Yb-176 → Yb-177 → Lu-177, then a chemical separation strips the ytterbium parent — leaving a Lu fraction in which essentially every atom is Lu-177. At the labelling bench, the DOTATATE / PSMA / FAPI peptide does not have to compete against bulk cold lutetium for the chelation site.
Based on: Dash A. et al., Production of ¹⁷⁷Lu for targeted radionuclide therapy: a review. Nucl. Med. Biol. 2015.
Read source ↗Specific activity → labelling yield
≥3,000 GBq/mg changes what you can label
Standard carrier-added Lu-177 typically lands around 600 GBq/mg. SHINE Medical n.c.a. ¹⁷⁷LuCl₃ delivers ≥3,000 GBq/mg at calibration with batch peaks near 3,700 GBq/mg. The ratio is roughly 5×. For the same therapeutic activity, n.c.a. lets the radiopharmacist label with five-fold less peptide mass — keeping the patient peptide dose low, the labelling yield high, and the tumour-to-background ratio clean on imaging.
Based on: Specific activity claims sourced to the SHINE FDA Drug Master File summary; benchmarked against EANM PRRT practical guidance.
Read source ↗Lu-177m — the kidney-dose argument
Negligible ¹⁷⁷ᵐLu means waste decays in days, not months
Carrier-added Lu-177 batches carry a metastable Lu-177m impurity (T½ ≈160 days). That long-lived contaminant contributes disproportionately to long-tail kidney dose during therapy and forces a long decay-store dwell for spent vials and patient excreta. n.c.a. production effectively eliminates Lu-177m — the spent-vial waste decays on the primary 6.65-day half-life, which is what the AERB-style decay-store rotation expects.
Based on: IAEA TECDOC-1955 Lu-177 production and quality; AERB Atomic Energy (Radiation Protection) Rules 2004.
Read source ↗208 keV imaging gamma
Built-in post-therapy SPECT/CT dosimetry
Lu-177 emits a 208 keV gamma (11 %) alongside the therapeutic β⁻. That is exactly the energy window a clinical SPECT camera maps for quantitative imaging. After each cycle, post-therapy SPECT/CT yields tumour and organ activity per voxel, feeding the dosimetry workflow EANM and AAPM TG-181 / TG-211 expect. n.c.a. activity per peptide is high enough to deliver clinical activity at low peptide mass — the imaging side stays clean.
Based on: EANM dosimetry guidance for radiopharmaceutical therapies; AAPM TG-181 PET/NM QA.
Read source ↗cGMP + FDA Drug Master File
Upstream regulatory dossier already assembled
SHINE Medical (Janesville, Wisconsin) produces the Lu-177 starting material under cGMP and ICH-Q7, with an FDA Drug Master File on file. For an Indian centre running an AERB-licensed theranostic programme, the upstream radionuclide dossier is already built — Saxsons supplies the AERB import licensing, sealed-source documentation and CDSCO-aligned paperwork on the India side.
Based on: ICH-Q7 Good Manufacturing Practice for Active Pharmaceutical Ingredients; FDA 21 CFR.
Read source ↗One n.c.a., three (and counting) targets
Same starting material across DOTATATE, PSMA and FAPI
A centre running PRRT alone today can extend the same SHINE-produced Lu-177 supply chain to PSMA-617 when the prostate clinic comes online, and to FAPI when the pancreatic-stroma protocol gets ethics approval — without re-qualifying the radionuclide. One Saxsons import line, one calibration schedule, three (and counting) clinical programmes downstream.
Based on: Saxsons supply-chain framing; consistent with the SHINE multi-target labelling examples.
Read source ↗Specification snapshot
≥3,000
GBq/mg
Specific activity at calibration
≥99.9 %
Radionuclidic purity
Ph. Eur. compliant
6.65 d
Half-life
β⁻ + 208 keV imaging γ
Negligible
Lu-177m
Spent-vial waste decays in days
Scope of this page
This page covers the upstream n.c.a. Lu-177 starting material. Target-specific knowledge — DOTATATE labelling for NETs, PSMA-617 labelling for mCRPC, FAPI labelling for tumour-stroma protocols — lives on the per-target knowledge hubs linked from the Where Next section. Activity-level claims and specific-activity figures are sourced to the SHINE FDA Drug Master File summary; clinical-protocol claims are sourced to peer-reviewed literature and EANM / AAPM guidelines.
Regulatory + production references
The IAEA, EANM and ICH documents that frame Lu-177 n.c.a. production, labelling and clinical use.
IAEA TECDOC-1955 — Production of Long Lived Parent Radionuclides for Generators
IAEA review of Lu-177 production routes, including the n.c.a. (Yb-176 → Yb-177 → Lu-177) pathway and quality-control expectations.
EANM — Practical guidance on PRRT with Lu-177
European Association of Nuclear Medicine procedural guidelines covering Lu-177 specific-activity, labelling-yield and dosimetry expectations.
ICH-Q7 — GMP for Active Pharmaceutical Ingredients
International Council for Harmonisation GMP guideline that frames upstream Lu-177 manufacturing.
AERB — Atomic Energy (Radiation Protection) Rules 2004
Indian regulatory framework for import, transport, decay-store and disposal of Lu-177 radionuclide consignments.
Literature Radar · auto-updated daily
Latest Lu-177 DOTATATE evidence
Fresh peer-reviewed papers on PRRT for neuroendocrine tumours, auto-updated from Europe PMC.
- Peer-ReviewedPubMedJournal of nuclear medicine · 2026
Radiopharmaceutical Therapy with [177Lu]Lu-DOTATATE in Refractory Meningiomas: Results from the French Multicenter MELUTE Cohort.
Garabedian N, Zaragori T, Tabouret E et al.
- Peer-ReviewedPubMedJCEM case reports · 2026
Unusual paraneoplastic thrombocytosis in small bowel neuroendocrine tumor responding to 177Lu-DOTATATE.
Piekarski E, Cottereau AS, Coriat R et al.
- Peer-ReviewedPubMedEndocrine-related cancer · 2026
Applying 177Lu-Dotatate for Hereditary Neuroendocrine Tumours: The Role in MEN1.
Becx MN, van Treijen MJC, Brabander T et al.
- 📖 Free full textPeer-ReviewedPubMedJCEM case reports · 2026
A case of metastasectomy following multiple courses of radionuclide therapy for distant metastatic pheochromocytoma.
Wada N, Kawata S, Obata Y et al.
- Peer-ReviewedPubMedThe Journal of clinical endocrinology and metabolism · 2026
Application of theranostics in thyroid cancer management.
Sridhar A, Behiri N, Klubo-Gwiezdzinska J.
Literature Radar · auto-updated daily
Latest Lu-177 PSMA evidence
Fresh peer-reviewed papers on theranostic therapy for mCRPC, auto-updated from Europe PMC.
- Peer-ReviewedPubMedWorld journal of urology · 2026
Survival outcomes with Lutetium-177-PSMA-617 in metastatic castration-resistant prostate cancer patient according to baseline tumor characteristics.
Wenzel M, Le QC, Siech C et al.
- Peer-ReviewedPubMedJournal of nuclear medicine · 2026
Multimodal Visual Question Answering System for Survival Prognosis in PSMA-Targeted Radiopharmaceutical Therapy.
Kassar M, Hu J, Rauscher I et al.
- Peer-ReviewedPubMedEuropean urology oncology · 2026
Machine Learning Models Combining [68Ga]Ga-PSMA-11 PET Radiomics and Clinical Features to Predict Overall Survival for Metastatic Castration-resistant Prostate Cancer Treated with [177Lu]Lu-PSMA Radioligand Therapy.
Edouard L, Papillon L, Ferrer L et al.
- Peer-ReviewedPubMedEuropean urology · 2026
177Lu-Prostate-specific Membrane Antigen Prior to Stereotactic Ablative Radiotherapy in Oligorecurrent Prostate Cancer: Secondary and Exploratory End Point Results from the Randomized Phase 2 LUNAR Trial.
Kishan AU, Wilhalme H, Felix C et al.
- Peer-ReviewedPubMedAnnals of nuclear medicine · 2026
PSMA-targeted radioligand therapy in prostate cancer: evidence hierarchy, platform maturity of ¹⁷⁷Lu-PSMA-617, and the clinical differentiation challenge for emerging radionuclides.
Lin ET.
Where next